Physician profile
Shahrokh E Rafii
NPI 1801873286
$5,330.59
in general payments reported to CMS, 2019-2025
32 companies · $601 in 2025
The $601 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $877 · 2020: $583 · 2021: $726 · 2022: $844 · 2023: $968 · 2024: $732 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,300.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,757.56 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $584.38 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $333.56 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $330.49 | 2021-2025 | Verquvo |
| Pfizer INC. | $307.21 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $282.05 | 2019-2023 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $241.70 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $170.91 | 2019-2021 | |
| Daiichi Sankyo INC. | $143.42 | 2022-2024 | Injectafer |
| Penumbra, INC. | $137.53 | 2020 | |
| Alnylam Pharmaceuticals INC. | $134.27 | 2020-2024 | Amvuttra |
| Chiesi USA, INC. | $129.65 | 2019-2024 | Kengreal |
| Medtronic, INC. | $78.05 | 2021-2024 | Corevalve Evolut R |
| Astellas Pharma US INC | $77.03 | 2020-2023 | Xtandi |
| Kestra Medical Technology Services, INC. | $76.52 | 2025 | Assure Wcd |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $73.16 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.78 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $50.88 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $46.51 | 2019-2020 | |
| Irhythm Technologies, INC. | $43.47 | 2024 | Zio Monitor, Zio Xt Patch |
| Arbor Pharmaceuticals, INC. | $36.55 | 2019 | |
| Biotronik INC. | $30.69 | 2020-2021 | |
| Octapharma USA, INC. | $27.35 | 2025 | Fibryga |
| Bardy Diagnostics, INC. | $26.32 | 2022 | |
| Smith+Nephew, INC. | $26.04 | 2022 | |
| Abbott Laboratories | $24.76 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $23.02 | 2023 | Inpefa |
| Amarin Pharma, INC. | $20.00 | 2019 | |
| Medtronic Vascular, INC. | $19.08 | 2020 | |
| Lundbeck LLC | $15.16 | 2019 | |
| Cardinal Health 200 LLC | $15.05 | 2021 | |
| Medtronic USA, INC. | $12.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahrokh Rafii listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.